Chimeric Antigen Receptor and Natural Killer Cells Expressing Same

{
  "publication_number": "US2026103502A1",
  "country": "US",
  "kind": "A1",
  "title": "Chimeric Antigen Receptor and Natural Killer Cells Expressing Same",
  "abstract": "The present invention provides a chimeric antigen receptor and natural killer cells expressing the same, and particularly, a chimeric antigen receptor (CAR) which includes an intracellular signaling domain including the whole or a portion of an OX40 ligand (CD252), thereby having excellent effects of increasing anticancer activity of immune cells, and immune cells expressing the same.",
  "claims": [
    "1. A chimeric antigen receptor, comprising: an intracellular signaling domain which includes the whole or a portion of OX40 ligand (CD252). 2. The chimeric antigen receptor according to claim 1, further comprising: a transmembrane domain linked to the intracellular signaling domain; a spacer domain linked to the transmembrane domain; and an extracellular domain linked to the spacer domain. 3. The chimeric antigen receptor according to claim 2, further comprising a signal sequence linked to the extracellular domain. 4. (canceled) 5. The chimeric antigen receptor according to claim 2, wherein the extracellular domain includes the whole or a portion of any one selected from the group consisting of an antigen-binding fragment of an antibody, a Fc receptor, a natural cytotoxicity receptor, NKG2D, 2B4 and DNAM-1. 6. (canceled) 7. The chimeric antigen receptor according to claim 5, wherein the antigen-binding fragment is a single-chain variable fragment (ScFv). 8.- 10. (canceled) 11. The chimeric antigen receptor according to claim 2, wherein the spacer domain includes the whole or a portion of any one selected from the group consisting of CD8a and CD28. 12. The chimeric antigen receptor according to claim 2, wherein the transmembrane domain includes the whole or a portion of any one selected from the group consisting of CD8a and CD28. 13. The chimeric antigen receptor according to claim 1, wherein the intracellular signaling domain further includes the whole or a portion of CD3-zeta. 14. (canceled) 15. A chimeric antigen receptor, comprising intracellular signaling domains which comprise: a first intracellular signaling domain including the whole or a portion of any one selected from the group consisting of CD28 and 4-1BB; a second intracellular signaling domain including the whole or a portion of OX40 ligand; and a third intracellular signaling domain including the whole or a portion of CD3-zeta, wherein the first, second and third intracellular signaling domains are arranged in order from a cell membrane toward an inside of the cell. 16. The chimeric antigen receptor according to claim 15, further comprising: a transmembrane domain linked to the intracellular signaling domain; a spacer domain linked to the transmembrane domain; and an extracellular domain linked to the spacer domain. 17. The chimeric antigen receptor according to claim 16, further comprising a signal sequence linked to the extracellular domain. 18. (canceled) 19. The chimeric antigen receptor according to claim 16, wherein the extracellular domain includes the whole or a portion of any one selected from the group consisting of an antigen-binding fragment of an antibody, a Fc receptor, a natural cytotoxicity receptor, NKG2D, 2B4 and DNAM-1. 20. The chimeric antigen receptor according to claim 16, wherein the spacer domain includes the whole or a portion of any one selected from the group consisting of CD8α and CD28. 21. The chimeric antigen receptor according to claim 16, wherein the transmembrane domain includes the whole or a portion of any one selected from the group consisting of CD8α and CD28. 22. The chimeric antigen receptor according to claim 15, wherein the first intracellular signaling domain includes the whole or a portion of CD28; the second intracellular signaling domain includes the whole or a portion of the OX40 ligand; and the third intracellular signaling domain includes the whole or a portion of CD3-zeta. 23. An immune cell expressing the chimeric antigen receptor according to claim 1. 24. The immune cell according to claim 23, wherein the immune cell is a natural killer cell (NK cell). 25. A pharmaceutical composition for treatment of tumor, comprising the immune cell according to claim 23 as an active ingredient. 26. (canceled) 27. A nucleic acid sequence encoding the chimeric antigen receptor according to claim 1. 28. (canceled) 29. (canceled) 30. A method for treatment of tumor, comprising administering the immune cell according to claim 23 to a subject."
  ],
  "cpc": [
    "C07K 14/7051",
    "A61K 2239/22",
    "A61K 2239/48",
    "A61K 2239/49",
    "A61K 2239/55",
    "A61K 40/15",
    "A61K 40/31",
    "A61K 40/4221",
    "A61K 40/4224",
    "C07K 16/2815",
    "C07K 16/2818",
    "C07K 16/283",
    "C07K 16/2851",
    "C07K 2317/622",
    "C07K 2317/73",
    "C07K 2319/03",
    "C07K 2319/33",
    "C12N 5/0646"
  ],
  "filing_date": "2025-09-08",
  "publication_date": "2026-04-16",
  "priority_date": "2016-12-28",
  "application_number": "US-202519322080-A"
}